Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of BL-M12D1 for injection (ADC) approved

Sichuan Biokin Pharmaceutical (688506.SH) announced that the company recently received the official Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), granting approval for the clinical trial of its independently developed innovative biologic drug BL-M12D1 for injection (ADC). BL-M12D1 for injection is an ADC drug derived from the same technology platform as iza-bren and sharing the same "linker + toxin" platform with Yizekang (lunconizumab tesirine, BL-B01D1/iza-bren). Its indication is relapsed or refractory hematological malignancies.